(PhysOrg.com) -- Pancreatic cancer remains one of the deadliest and hardest to treat cancers. After diagnosis, patients tend to live only six months and less than 5 percent survive to five years.
In terms of a patient population, there is very little we can do for them once we find the cancer, said Craig Thompson, M.D., director of the Abramson Cancer Center at the University of Pennsylvania.
The currently available treatment is gemcitabine, which is sold as
Gemzar by Eli Lilly and Company, but the response rate with this
treatment is typically only 5 percent. Researchers are working to
develop new ways of treating pancreatic cancer and early scientific
studies are showing promise... Read More